1. Home
  2. SLM vs ADMA Comparison

SLM vs ADMA Comparison

Compare SLM & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLM Corporation

SLM

SLM Corporation

HOLD

Current Price

$27.08

Market Cap

5.7B

Sector

Finance

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$19.86

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLM
ADMA
Founded
1972
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7B
4.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLM
ADMA
Price
$27.08
$19.86
Analyst Decision
Buy
Strong Buy
Analyst Count
13
2
Target Price
$32.54
$28.50
AVG Volume (30 Days)
3.5M
2.9M
Earning Date
01-22-2026
11-05-2025
Dividend Yield
1.93%
N/A
EPS Growth
N/A
205.35
EPS
2.84
0.86
Revenue
$1,460,617,000.00
$488,559,000.00
Revenue This Year
$6.00
$22.19
Revenue Next Year
$16.24
$24.33
P/E Ratio
$9.46
$23.11
Revenue Growth
N/A
27.63
52 Week Low
$23.81
$13.50
52 Week High
$34.97
$25.67

Technical Indicators

Market Signals
Indicator
SLM
ADMA
Relative Strength Index (RSI) 42.14 66.02
Support Level $24.87 $19.13
Resistance Level $27.94 $20.22
Average True Range (ATR) 0.88 0.73
MACD -0.31 0.05
Stochastic Oscillator 32.96 79.44

Price Performance

Historical Comparison
SLM
ADMA

About SLM SLM Corporation

SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Share on Social Networks: